CN105254634A - 用于治疗过度增殖疾病和血管发生相关性疾病的2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物 - Google Patents

用于治疗过度增殖疾病和血管发生相关性疾病的2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物 Download PDF

Info

Publication number: CN105254634A
Authority: CN; China
Prior art keywords: base; quinazoline; glyoxalidine; methoxyl group; morpholine
Prior art date: 2006-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CN201510632842.3A

Other languages

English (en)

Chinese (zh)

Other versions

CN105254634B (zh

Inventor

M.亨特曼

J.伍德

W.斯科特

M.米歇尔斯

A.M.坎贝尔

A.M.比利翁

R.B.罗利

A.雷德曼

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bayer Pharma AG

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-05

Filing date

2007-12-05

Publication date

2016-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105254634(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-05 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2016-01-20 Publication of CN105254634A publication Critical patent/CN105254634A/zh

2022-05-27 Application granted granted Critical

2022-05-27 Publication of CN105254634B publication Critical patent/CN105254634B/zh

Status Active legal-status Critical Current

2027-12-05 Anticipated expiration legal-status Critical

Links

0 CCC(COc(ccc1c2N=C(NC(*)=O)N3C1=NCC3)c2OC)OCCN* Chemical compound CCC(COc(ccc1c2N=C(NC(*)=O)N3C1=NCC3)c2OC)OCCN* 0.000 description 3
FYGIAJGIHGLMOC-UHFFFAOYSA-N CCCc1nc(N)ncc1C(O)=O Chemical compound CCCc1nc(N)ncc1C(O)=O FYGIAJGIHGLMOC-UHFFFAOYSA-N 0.000 description 1
FMAVYGFEZZVXDM-UHFFFAOYSA-N Cc1c(C(NNc(c(C2=NCCN2C)ccc2OCCCN3CCOCC3)c2OC)=O)[s]c(N)n1 Chemical compound Cc1c(C(NNc(c(C2=NCCN2C)ccc2OCCCN3CCOCC3)c2OC)=O)[s]c(N)n1 FMAVYGFEZZVXDM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

CN201510632842.3A 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物 Active CN105254634B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US87309006P	2006-12-05	2006-12-05
US60/873090		2006-12-05
CN200780044849.7A CN101631464B (zh)	2006-12-05	2007-12-05	用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN200780044849.7A Division CN101631464B (zh)	2006-12-05	2007-12-05	用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Publications (2)

Publication Number	Publication Date
CN105254634A true CN105254634A (zh)	2016-01-20
CN105254634B CN105254634B (zh)	2022-05-27

Family

ID=39492563

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CN200780044849.7A Active CN101631464B (zh)	2006-12-05	2007-12-05	用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN201510632842.3A Active CN105254634B (zh)	2006-12-05	2007-12-05	用于治疗过度增殖疾病和血管发生相关性疾病的2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物
CN202211453281.7A Pending CN115724847A (zh)	2006-12-05	2007-12-05	2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN201810535933.9A Active CN108774232B (zh)	2006-12-05	2007-12-05	2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CN200780044849.7A Active CN101631464B (zh)	2006-12-05	2007-12-05	用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
CN202211453281.7A Pending CN115724847A (zh)	2006-12-05	2007-12-05	2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN201810535933.9A Active CN108774232B (zh)	2006-12-05	2007-12-05	2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物

Country Status (42)

Country	Link
US (3)	USRE46856E1 (und)
EP (1)	EP2096919B1 (und)
JP (1)	JP5326092B2 (und)
KR (1)	KR101501785B1 (und)
CN (4)	CN101631464B (und)
AR (1)	AR064106A1 (und)
AU (1)	AU2007328008B2 (und)
BR (1)	BRPI0720178B8 (und)
CA (1)	CA2671614C (und)
CL (1)	CL2007003508A1 (und)
CO (1)	CO6220908A2 (und)
CR (1)	CR10838A (und)
CU (1)	CU23796B7 (und)
DK (1)	DK2096919T3 (und)
DO (1)	DOP2009000135A (und)
EA (1)	EA018839B1 (und)
EC (1)	ECSP099387A (und)
ES (1)	ES2572189T3 (und)
GT (1)	GT200900154A (und)
HK (1)	HK1217953A1 (und)
HN (1)	HN2009001131A (und)
HU (1)	HUE028773T2 (und)
IL (1)	IL198273A (und)
JO (1)	JO3147B1 (und)
MA (1)	MA31283B1 (und)
MX (1)	MX2009006001A (und)
MY (1)	MY157944A (und)
NO (1)	NO342348B1 (und)
NZ (1)	NZ577342A (und)
PA (1)	PA8759601A1 (und)
PE (1)	PE20081444A1 (und)
PL (1)	PL2096919T3 (und)
RS (1)	RS56045B1 (und)
SG (1)	SG177170A1 (und)
SI (1)	SI2096919T1 (und)
SV (1)	SV2009003288A (und)
TN (1)	TN2009000137A1 (und)
TW (1)	TWI406662B (und)
UA (1)	UA96965C2 (und)
UY (1)	UY30761A1 (und)
WO (1)	WO2008070150A1 (und)
ZA (1)	ZA200904691B (und)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2244721A4 (en) *	2008-01-14	2017-01-18	Bayer Intellectual Property GmbH	Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168582A1 (en)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) *	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
CA2735932C (en) *	2008-09-30	2013-07-09	Pfizer Inc.	Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2184276A1 (en)	2008-11-07	2010-05-12	Universite Paul Cezanne Aix-Marseille Iii	Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
JP5569397B2 (ja) *	2009-01-16	2014-08-13	ダイソー株式会社	２−ヒドロキシメチルモルホリン塩の製造方法
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102958540B (zh)	2010-04-16	2015-09-02	拜耳知识产权有限责任公司	含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
BR112013004882A2 (pt)	2010-08-31	2016-05-03	Snu R&Db Foundation	utilização de reprogramação fetal de agonista ppar delta
UA113280C2 (xx) *	2010-11-11	2017-01-10		АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JP6165058B2 (ja) *	2010-11-11	2017-07-19	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	アルコキシ−置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン
WO2012062743A1 (en)	2010-11-11	2012-05-18	Bayer Pharma Aktiengesellschaft	Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
JO3733B1 (ar) *	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2861256B1 (en)	2012-06-15	2019-10-23	The Brigham and Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
EP2914260A1 (en)	2012-10-31	2015-09-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
KR102185175B1 (ko) *	2012-11-02	2020-12-02	티지 쎄라퓨틱스, 인코포레이티드	항cd20 항체와 pi3 키나아제 선택적 억제제의 조합물
CN103214489B (zh) *	2013-02-25	2016-10-26	中国人民解放军第二军医大学	一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
EA037577B1 (ru)	2013-04-08	2021-04-16	Байер Фарма Акциенгезельшафт	ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ)
CN104557955B (zh) *	2013-10-23	2017-05-03	上海汇伦生命科技有限公司	作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途
US20150148345A1 (en) *	2013-11-26	2015-05-28	Gilead Sciences, Inc.	Therapies for treating myeloproliferative disorders
US10124007B2 (en)	2013-12-03	2018-11-13	Bayer Pharma Aktiengesellschaft	Combination of PI3K-inhibitors
US10117874B2 (en)	2013-12-03	2018-11-06	Bayer Pharma Aktiengesellschaft	Combination of PI3K-inhibitors
TWI533871B (zh)	2014-03-11	2016-05-21	國立中央大學	萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
TWI533869B (zh)	2014-03-11	2016-05-21	國立中央大學	蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
FR3018813B1 (fr) *	2014-03-18	2016-04-15	Maco Pharma Sa	Procede de synthese d'un derive de psoralene
WO2016059220A1 (en)	2014-10-16	2016-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Tcr-activating agents for use in the treatment of t-all
EP3018131A1 (en) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthesis of copanlisib and its dihydrochloride salt
AU2016231260A1 (en) *	2015-03-09	2017-09-21	Bayer Healthcare Pharmaceuticals Inc.	Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
KR20180013851A (ko) *	2015-03-09	2018-02-07	바이엘 파마 악티엔게젤샤프트	치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
FR3033499A1 (fr) *	2015-03-11	2016-09-16	Centre Leon-Berard	Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3317284B1 (en) *	2015-07-02	2019-10-30	H. Hoffnabb-La Roche Ag	Benzoxazepin oxazolidinone compounds and methods of use
CN105130997B (zh) *	2015-09-25	2017-12-05	苏州明锐医药科技有限公司	一种库潘尼西的制备方法
CN105130998B (zh) *	2015-09-25	2017-07-28	苏州立新制药有限公司	库潘尼西的制备方法
US10844066B2 (en)	2016-03-08	2020-11-24	Bayer Pharma Aktiengesellschaft	2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
EP3219329A1 (en)	2016-03-17	2017-09-20	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib
JP7079937B2 (ja)	2016-05-26	2022-06-03	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケイション	肺血管疾患を治療するための組成物および方法
WO2017211248A1 (zh) *	2016-06-08	2017-12-14	深圳市塔吉瑞生物医药有限公司	一种取代的咪唑并喹唑啉化合物及其药物组合物
US10925880B2 (en)	2016-09-23	2021-02-23	Bayer Pharma Aktiengesellschaft	Combination of PI3K-inhibitors
CN106177918A (zh) *	2016-09-30	2016-12-07	广州赛莱拉干细胞科技股份有限公司	一种间充质干细胞注射液及其制备方法和应用
JP2020503289A (ja)	2016-12-14	2020-01-30	ターベダセラピューティクスインコーポレイテッドＴａｒｖｅｄａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｈｓｐ９０標的化コンジュゲート及びその製剤
EP3585437B1 (en)	2017-02-24	2022-12-21	Bayer Pharma Aktiengesellschaft	Combinations of copanlisib with anti-pd-1 antibody
WO2018215282A1 (en)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combination of bub1 and pi3k inhibitors
US11185549B2 (en)	2017-06-28	2021-11-30	Bayer Consumer Care Ag	Combination of a PI3K-inhibitor with an androgen receptor antagonist
WO2019010491A1 (en) *	2017-07-07	2019-01-10	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
JP6916562B2 (ja) *	2017-08-11	2021-08-11	テリジーンリミテッドＴｅｌｉｇｅｎｅＬｔｄ．	化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤
MA50068A (fr)	2017-09-08	2021-06-02	Bayer Consumer Care Ag	Formulations de copanlisib
EP3498266A1 (en)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulations of copanlisib
WO2019105734A1 (en)	2017-11-28	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib
WO2019105835A1 (en)	2017-11-29	2019-06-06	Bayer Consumer Care Ag	Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en)	2018-04-11	2019-10-17	Bayer Aktiengesellschaft	Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
CN108383849B (zh) *	2018-04-26	2020-11-06	浙江大学	咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
CN108841318A (zh) *	2018-07-12	2018-11-20	中国科学院海洋研究所	一种自修复壳聚糖水凝胶防腐涂料及其合成方法
US20210187134A1 (en)	2018-08-28	2021-06-24	Bayer As	Combination of pi3k-inhibitors and targeted thorium conjugates
CA3116230A1 (en)	2018-10-16	2020-04-23	Bayer Aktiengesellschaft	Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN109516961B (zh) *	2018-12-25	2021-01-01	浙江大学	氨基喹唑啉酮和氨基异喹啉酮衍生物及其应用
WO2020164997A1 (en)	2019-02-12	2020-08-20	Bayer Aktiengesellschaft	Combination of pi3k-inhibitors
WO2023139125A1 (en)	2022-01-18	2023-07-27	Synthon B.V.	Improved process for preparation of copanlisib
WO2023218032A1 (en)	2022-05-13	2023-11-16	Synthon B.V.	Solid forms of copanlisib salts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644354A (en)	1968-09-16	1972-02-22	Sandoz Ag	5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en) *	1978-04-10	1979-03-27	Bristol-Myers Company	Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US6608053B2 (en) *	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
EP1277754B8 (en) *	2000-04-27	2005-09-28	Astellas Pharma Inc.	Imidazopyridine derivatives
PA8578001A1 (es) *	2002-08-07	2004-05-07	Warner Lambert Co	Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
ES2367141T3 (es) *	2002-09-30	2011-10-28	Bayer Pharma Aktiengesellschaft	Derivados de azol-pirimidina condensados.
AT412873B (de)	2004-02-20	2005-08-25	Aop Orphan Pharmaceuticals Ag	Verfahren zur herstellung von anagrelid hydrochlorid
WO2007143483A2 (en)	2006-06-01	2007-12-13	Smithkline Beecham Corporation	Combination of pazopanib and lapatinib for treating cancer
WO2008002039A1 (en)	2006-06-28	2008-01-03	Hanmi Pharm. Co., Ltd.	Quinazoline derivatives for inhibiting the growth of cancer cell
EP2508525A1 (en)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

2007
- 2007-12-03 AR ARP070105390A patent/AR064106A1/es active IP Right Grant
- 2007-12-04 PA PA20078759601A patent/PA8759601A1/es unknown
- 2007-12-04 PE PE2007001709A patent/PE20081444A1/es active IP Right Grant
- 2007-12-04 JO JOP/2007/0517A patent/JO3147B1/ar active
- 2007-12-04 TW TW096145999A patent/TWI406662B/zh active
- 2007-12-04 UY UY30761A patent/UY30761A1/es not_active Application Discontinuation
- 2007-12-05 SI SI200731771A patent/SI2096919T1/sl unknown
- 2007-12-05 CN CN200780044849.7A patent/CN101631464B/zh active Active
- 2007-12-05 CN CN201510632842.3A patent/CN105254634B/zh active Active
- 2007-12-05 AU AU2007328008A patent/AU2007328008B2/en active Active
- 2007-12-05 EP EP07862580.3A patent/EP2096919B1/en active Active
- 2007-12-05 NZ NZ577342A patent/NZ577342A/en unknown
- 2007-12-05 ES ES07862580T patent/ES2572189T3/es active Active
- 2007-12-05 CA CA2671614A patent/CA2671614C/en active Active
- 2007-12-05 CN CN202211453281.7A patent/CN115724847A/zh active Pending
- 2007-12-05 PL PL07862580T patent/PL2096919T3/pl unknown
- 2007-12-05 US US15/398,916 patent/USRE46856E1/en active Active
- 2007-12-05 UA UAA200906701A patent/UA96965C2/ru unknown
- 2007-12-05 KR KR1020097011551A patent/KR101501785B1/ko active IP Right Grant
- 2007-12-05 CN CN201810535933.9A patent/CN108774232B/zh active Active
- 2007-12-05 CL CL200703508A patent/CL2007003508A1/es unknown
- 2007-12-05 MY MYPI20092044A patent/MY157944A/en unknown
- 2007-12-05 SG SG2011088887A patent/SG177170A1/en unknown
- 2007-12-05 HU HUE07862580A patent/HUE028773T2/en unknown
- 2007-12-05 JP JP2009540293A patent/JP5326092B2/ja active Active
- 2007-12-05 US US12/517,875 patent/US8466283B2/en not_active Ceased
- 2007-12-05 DK DK07862580.3T patent/DK2096919T3/en active
- 2007-12-05 WO PCT/US2007/024985 patent/WO2008070150A1/en active Application Filing
- 2007-12-05 MX MX2009006001A patent/MX2009006001A/es active IP Right Grant
- 2007-12-05 EA EA200900733A patent/EA018839B1/ru not_active IP Right Cessation
- 2007-12-05 BR BRPI0720178A patent/BRPI0720178B8/pt active IP Right Grant
- 2007-12-05 RS RS20170561A patent/RS56045B1/sr unknown
2009
- 2009-04-13 TN TNP2009000137A patent/TN2009000137A1/fr unknown
- 2009-04-21 IL IL198273A patent/IL198273A/en active IP Right Grant
- 2009-06-04 CO CO09057915A patent/CO6220908A2/es active IP Right Grant
- 2009-06-04 EC EC2009009387A patent/ECSP099387A/es unknown
- 2009-06-04 HN HN2009001131A patent/HN2009001131A/es unknown
- 2009-06-05 CU CU20090103A patent/CU23796B7/es active IP Right Grant
- 2009-06-05 DO DO2009000135A patent/DOP2009000135A/es unknown
- 2009-06-05 SV SV2009003288A patent/SV2009003288A/es unknown
- 2009-06-05 CR CR10838A patent/CR10838A/es unknown
- 2009-06-05 GT GT200900154A patent/GT200900154A/es unknown
- 2009-06-29 MA MA32057A patent/MA31283B1/fr unknown
- 2009-07-03 ZA ZA200904691A patent/ZA200904691B/xx unknown
- 2009-07-03 NO NO20092529A patent/NO342348B1/no unknown
2013
- 2013-06-03 US US13/908,566 patent/US20130261113A1/en not_active Abandoned
2016
- 2016-05-26 HK HK16106013.2A patent/HK1217953A1/zh unknown

Also Published As

Publication number	Publication date
UY30761A1 (es)	2008-07-03
NO20092529L (no)	2009-08-27
IL198273A0 (en)	2009-12-24
CN108774232A (zh)	2018-11-09
CO6220908A2 (es)	2010-11-19
HUE028773T2 (en)	2017-01-30
HK1217953A1 (zh)	2017-01-27
PA8759601A1 (es)	2009-02-09
ZA200904691B (en)	2010-09-29
HN2009001131A (es)	2012-02-06
TW200840582A (en)	2008-10-16
PL2096919T3 (pl)	2016-08-31
IL198273A (en)	2015-07-30
AU2007328008A1 (en)	2008-06-12
PE20081444A1 (es)	2008-11-29
TWI406662B (zh)	2013-09-01
WO2008070150A1 (en)	2008-06-12
EP2096919A4 (en)	2010-11-17
TN2009000137A1 (en)	2010-10-18
EA200900733A1 (ru)	2009-12-30
KR101501785B1 (ko)	2015-03-11
MA31283B1 (fr)	2010-04-01
BRPI0720178B1 (pt)	2019-04-09
KR20090096440A (ko)	2009-09-10
CA2671614C (en)	2016-01-26
SV2009003288A (es)	2009-10-02
US8466283B2 (en)	2013-06-18
MX2009006001A (es)	2009-06-16
CN115724847A (zh)	2023-03-03
JO3147B1 (ar)	2017-09-20
EP2096919A1 (en)	2009-09-09
CN101631464B (zh)	2022-12-06
CN108774232B (zh)	2022-08-09
DOP2009000135A (es)	2009-06-30
AU2007328008B2 (en)	2014-03-13
AR064106A1 (es)	2009-03-11
CN105254634B (zh)	2022-05-27
CU23796B7 (es)	2012-03-15
CU20090103A7 (es)	2011-12-28
UA96965C2 (ru)	2011-12-26
ECSP099387A (es)	2009-11-30
SG177170A1 (en)	2012-01-30
NO342348B1 (no)	2018-05-07
CR10838A (es)	2009-11-05
US20110083984A1 (en)	2011-04-14
JP5326092B2 (ja)	2013-10-30
JP2010511718A (ja)	2010-04-15
CA2671614A1 (en)	2008-06-12
EP2096919B1 (en)	2016-03-02
NZ577342A (en)	2012-01-12
RS56045B1 (sr)	2017-09-29
SI2096919T1 (sl)	2016-06-30
GT200900154A (es)	2012-01-17
ES2572189T3 (es)	2016-05-30
CN101631464A (zh)	2010-01-20
CL2007003508A1 (es)	2008-07-04
USRE46856E1 (en)	2018-05-22
BRPI0720178B8 (pt)	2021-05-25
BRPI0720178A2 (pt)	2013-12-24
MY157944A (en)	2016-08-30
DK2096919T3 (en)	2016-05-17
EA018839B1 (ru)	2013-11-29
US20130261113A1 (en)	2013-10-03

Legal Events

Date	Code	Title	Description
2016-01-20	C06	Publication
2016-01-20	PB01	Publication
2016-02-17	C10	Entry into substantive examination
2016-02-17	SE01	Entry into force of request for substantive examination
2017-01-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1217953 Country of ref document: HK
2022-05-27	GR01	Patent grant
2022-05-27	GR01	Patent grant
2023-09-29	CP02	Change in the address of a patent holder	Address after: On the Rhine River, Germany Patentee after: BAYER INTELLECTUAL PROPERTY GmbH Address before: Germany Patentee before: BAYER INTELLECTUAL PROPERTY GmbH
2023-09-29	CP02	Change in the address of a patent holder

Publication	Publication Date	Title
CN105254634A (zh)	2016-01-20	用于治疗过度增殖疾病和血管发生相关性疾病的2，3-二氢咪唑并[1，2-c]喹唑啉取代衍生物
US10226469B2 (en)	2019-03-12	Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines for treating lymphomas
US8859572B2 (en)	2014-10-14	Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
US10202385B2 (en)	2019-02-12	Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines
CN102906094A (zh)	2013-01-30	用于治疗过度增殖性病症和与血管发生相关的疾病的氨基醇取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物
CN103370320B (zh)	2016-04-27	芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103339133A (zh)	2013-10-02	烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
EP2168582A1 (en)	2010-03-31	Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines